Print pageEmail pageRSS Feeds

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2015 | 2014 | 2013 | 2012
DateTitle 
04/29/15ARIAD Enters into Settlement Agreement with Sarissa Capital Management
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it has reached an agreement to settle its current proxy contest with Sarissa Capital Management. In addition, ARIAD’s founder, Harvey J. Berger, M.D., has informed the Board of Directors of his decision to retire as chairman and chief executive officer (CEO) upon appointment of his successor or December 31, 2015, whichever is earlier. ... 
Printer Friendly Version
04/29/15ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that its founder, Harvey J. Berger, M.D., has informed the Board of his decision to retire as chairman and chief executive officer (CEO) upon the appointment of his successor or December 31, 2015, whichever is earlier. The Board has begun a comprehensive search to identify Dr. Berger’s successor. Dr. Berger has also agreed to serve as a spe... 
Printer Friendly Version
04/23/15ARIAD to Webcast Conference Call on First Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 23, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2015 financial results on Thursday, May 7, 2015, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visit... 
Printer Friendly Version
04/22/15ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 22, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the issuance of its first U.S. patent on brigatinib, ARIAD’s investigational ALK inhibitor. The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, “Phosphorous Derivatives as Kinase Inhibitors.” The patent provides composition-of-matter protection through at least December 30, 2030 for ARIAD’s inve... 
Printer Friendly Version
04/21/15ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Apr. 21, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at the American Association for Cancer Research (AACR) Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-... 
Printer Friendly Version
04/17/15ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
GENEVA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The new results include an analysis of safety and efficacy for patients treated at select doses o... 
Printer Friendly Version
04/06/15ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 6, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that Health Canada has approved the use of Iclusig™ (as ponatinib hydrochloride) in Canada for the treatment of adult patients with all phases of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML ... 
Printer Friendly Version
03/25/15ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 25, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig® (ponatin... 
Printer Friendly Version
03/24/15ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel
CAMBRIDGE, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--Mar. 24, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig® (ponatinib) in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid ... 
Printer Friendly Version
03/19/15ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place Saturday, April 18 through Wednesday, April 22, 2015, in Philadelphia. The schedule and meeting locations for the four ARIAD sessions, including an oral presentation on the discovery of ... 
Printer Friendly Version
03/10/15ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 10, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced today that the United States District Court for the District of Massachusetts dismissed the shareholder derivative lawsuit filed in late 2013 against the Company and certain of its officers and directors in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig® (ponatinib) on October ... 
Printer Friendly Version
02/24/15ARIAD to Present at the Cowen and Company 35th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 35th Annual Health Care Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Monday, March 2, at 2:10 p.m. (ET). The ARIAD presentation will be webcast live and can be accessed by visi... 
Printer Friendly Version
02/20/15ARIAD Confirms Receipt of Sarissa Capital Management’s Nomination of Director Candidates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today confirmed that it has received notice of nomination by Sarissa Capital Management LP of two director candidates for election at the 2015 Annual Meeting. ARIAD has no further comment at this time. About ARIAD ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncol... 
Printer Friendly Version
02/19/15ARIAD Reports 2014 Financial Results, Provides 2015 Financial Guidance and Outlines Strategic Objectives
Iclusig Net Product Revenue Guidance for 2015 in the Range of $130 Million to $140 Million Three New Iclusig Clinical Trials Planned to Begin This Year CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2014 and issued 2015 financial guidance. Additionally, the Company provided an update on corporat... 
Printer Friendly Version
02/11/15ARIAD to Present at the RBC Capital Markets’ Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 11, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it will present at the RBC Capital Markets’ Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 25, at 8:00 a.m. (ET). The ARIAD presentation at the RBC Capital Markets’ Healthcare Conference ... 
Printer Friendly Version
02/03/15ARIAD to Present at the Leerink Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Thursday, February 12, at 3:30 p.m. (ET). The ARIAD presentation at the Leerink Global Healthcare Conference will be ... 
Printer Friendly Version
01/29/15ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2014 financial results and issue 2015 financial guidance on Thursday, February 19, 2015, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate upd... 
Printer Friendly Version
01/22/15ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. ... 
Printer Friendly Version
01/20/15ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe
Legally Binding Decision Follows Recommendations of Pharmacovigilance Risk Assessment Committee Review CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Jan. 20, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig® (ponatinib) following recommendations made by the Pharmacovi... 
Printer Friendly Version
01/13/15ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years
Iclusig Commercial Opportunity Expected to Expand -- Three New Clinical Trials to Begin in 2015, including a Global, Randomized Trial of Iclusig vs. Nilotinib in Second-Line CML CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 20... 
Printer Friendly Version
01/06/15ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
Randomized Global Trial to Evaluate Safety and Efficacy of Iclusig at Three Starting Doses CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig® (ponatinib) in patients with refractory, chronic-phase chron... 
Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue